NKTR

Nektar Therapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 4/10
  • Value↓ 0/10
Nektar Therapeutics sales and earnings growth
NKTR Growth
Neutral
  • Revenue Y/Y↓ -87.77%
  • EPS Y/Y↓ 0.00%
  • FCF Y/Y↓ -87.30%
Nektar Therapeutics gross and profit margin trends
NKTR Profitability
Low
  • Gross margin ↑ 354.90%
  • EPS margin↓ -1737.90%
  • ROIC 5Y↓ -43.62%
Nektar Therapeutics net debt vs free cash flow
NKTR Risk
Great
  • Debt / Equity↓ 1.0
  • Debt / FCF↓ 0.3
  • Interest coverage↓ -7.6

Nektar Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗